RegenXBio (RGNX)

RegenXBio (RGNX) Financial Statements


RegenXBio Financial Overview

RegenXBio's market cap is currently ―. The company's EPS TTM is $-6.497; its P/E ratio is -3.10; RegenXBio is scheduled to report earnings on May 9, 2023, and the estimated EPS forecast is $-1.42. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue$ 31.34M$ 26.51M$ 32.65M$ 22.22M$ 398.65M
Gross Profit$ 18.56M$ 13.42M$ 19.70M$ 6.50M$ 375.60M
EBIT$ -55.67M$ -69.53M$ -61.32M$ -70.63M$ 313.93M
EBITDA$ -51.54M$ -65.98M$ -58.68M$ -68.04M$ 316.53M
Net Income Common Stockholders$ -59.94M$ -75.48M$ -68.18M$ -76.72M$ 294.02M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 364.64M$ 382.42M$ 402.96M$ 394.13M$ 457.44M
Total Assets$ 833.27M$ 883.79M$ 953.44M$ 1.03B$ 1.11B
Total Debt$ 94.80M$ 88.28M$ 88.50M$ 87.69M$ 86.68M
Net Debt$ -269.84M$ -294.14M$ -314.46M$ -306.44M$ -370.76M
Total Liabilities$ 317.07M$ 319.97M$ 322.93M$ 335.70M$ 349.61M
Stockholders Equity$ 516.20M$ 563.82M$ 630.52M$ 689.67M$ 764.30M
Cash Flow-
Free Cash Flow$ -44.84M$ -55.51M$ -70.99M$ -66.88M$ 311.62M
Operating Cash Flow$ -39.37M$ -50.46M$ -61.75M$ -55.91M$ 326.24M
Investing Cash Flow$ 26.70M$ 53.04M$ -1.08M$ -90.59M$ -216.36M
Financing Cash Flow$ -8.92M$ -5.42M$ -7.67M$ -6.83M$ 7.64M
Currency in USD

RegenXBio Earnings and Revenue History

RegenXBio Debt to Assets

RegenXBio Cash Flow

RegenXBio Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis